ADVL1414, A Phase 1 Study of Selinexor (KPT-330), a Selective XP01 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Study of Selinexor in Pediatric Solid Tumors, including CNS Tumors
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAQ4204
U.S. Govt. ID: NCT02323880
Contact: Luca Szalontay, MD: 212-305-9770 /
Additional Study Information: We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects selinexor can cause; To learn more about the pharmacology (how your body handles the drug) of selinexor; To learn more about the biology of selinexor in blood and tumor tissue; To determine whether selinexor is a beneficial treatment for your tumor.
This study is closed
Luca Szalontay, MD
Do You Qualify?
Does your child have a solid tumor, including lymphoma and CNS tumors, or a glioma? Yes No
Is your child between 12 months to 21 years of age? Yes No
Has your child received a solid organ transplantation? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Luca Szalontay, MD